---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-24-012549"
form_type: "8-K"
ticker: "PTN"
cik: "0000911216"
company_name: "PALATIN TECHNOLOGIES INC"
filed_at: "2024-10-01T23:59:59+00:00"
generated_at: "2026-05-31T00:17:17.986435+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Palatin reports FY2024 net loss $29.7M, cash $9.5M; outlines clinical milestones for obesity, DED, ED, UC

## Summary
- Net loss for FY2024 $29.7M ($2.02 per share) vs $24.0M ($2.21) prior year; revenue declined as Vyleesi asset sold.
- Cash and cash equivalents $9.5M at June 30, 2024; auditor includes going concern explanatory paragraph.
- Obesity Phase 2 MC4R+GLP-1 trial enrollment to complete early Q4 2024; topline results expected Q1 2025.
- DED Phase 3 MELODY-2/3 trials to start enrollment Q1 2025; topline results anticipated Q4 2025.
- Diabetic nephropathy Phase 2 BREAKOUT topline results expected Q4 2024; UC Phase 2 interim readout Q4 2024.

## SEC filing metadata
- accession: 0001654954-24-012549
- form_type: 8-K
- ticker: PTN
- cik: 0000911216
- company_name: PALATIN TECHNOLOGIES INC
- filed_at: 2024-10-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/911216/000165495424012549/0001654954-24-012549-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/911216/000165495424012549/ptn_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-24-012549
- JSON: https://secwatch.observer/filing/0001654954-24-012549.json
- Plain text: https://secwatch.observer/filing/0001654954-24-012549.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.